{
    "clinical_study": {
        "@rank": "73856", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1: Lenalidomide + Dexamethasone", 
                "arm_group_type": "Experimental", 
                "description": "Lenalidomide 25 mg capsules by mouth once daily (on Days 1-21), repeat every 28 days until subject meets criteria for discontinuation of study drug\nDexamethasone 40 mg tablets by mouth weekly (on Days 1, 8, 15, 22), repeat every 28 days until subject meets criteria for discontinuation of study drug"
            }, 
            {
                "arm_group_label": "Arm 2: Lenalidomide + Dexamethasone + Elotuzumab", 
                "arm_group_type": "Experimental", 
                "description": "Lenalidomide 25 mg capsules by mouth once daily (Days 1-21)\nDexamethasone 28 mg tablets by mouth once daily [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15(cycles 3-18); Day 1 (cycle 19 & beyond)]\nDexamethasone 40 mg tablets by mouth once daily [Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 & beyond)]\nDexamethasone 8 mg IV (intravenous) solution once daily [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15 (cycles 3-18); Day 1 (cycle 19 & beyond)]\nElotuzumab 10 mg/kg IV solution weekly [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15 (cycles 3-18)]\nElotuzumab 20 mg/kg IV solution on Day 1 (cycle 19 & beyond)\nRepeat above-mentioned dose cycles every 28 days until subject meets criteria for discontinuation of study drug"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to look at subjects who receive Lenalidomide, Dexamethasone, and\n      Elotuzumab and determine if they will have lower surface CS1 expression on malignant plasma\n      cells at the time of progression than those who receive Lenalidomide and Dexamethasone\n      without Elotuzumab"
        }, 
        "brief_title": "PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Newly Diagnosed, Previously Untreated Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com.\n\n        Inclusion Criteria:\n\n        Subjects who are newly diagnosed with symptomatic MM and who:\n\n          -  Have not received any prior systemic anti-myeloma therapy\n\n          -  Have measurable disease\n\n          -  And are not candidates for high-dose therapy plus stem-cell transplantation (SCT)\n             because of age (\u226565 years) or coexisting conditions. Refusal to undergo high dose\n             therapy with SCT is NOT sufficient for entry onto CA204-006 for a subject <65 years\n             old. There must be a comorbidity that prevents SCT for a subject <65 years old\n\n        Exclusion Criteria:\n\n          -  Subjects with non-secretory or oligo-secretory or free light-chain only myeloma\n\n          -  Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions\n\n          -  Monoclonal Gammopathy of Undetermined Significance (MGUS)\n\n          -  Active plasma cell leukemia\n\n          -  Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01891643", 
            "org_study_id": "CA204-006 (Biomarker Substudy)", 
            "secondary_id": "2010-022445-20"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1: Lenalidomide + Dexamethasone", 
                    "Arm 2: Lenalidomide + Dexamethasone + Elotuzumab"
                ], 
                "intervention_name": "Lenalidomide", 
                "intervention_type": "Drug", 
                "other_name": "Revlimid\u00ae"
            }, 
            {
                "arm_group_label": [
                    "Arm 1: Lenalidomide + Dexamethasone", 
                    "Arm 2: Lenalidomide + Dexamethasone + Elotuzumab"
                ], 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Decadron\u00ae", 
                    "Dexamethasone Intensol\u00ae", 
                    "Dexpak\u00ae", 
                    "Taperpak\u00ae"
                ]
            }, 
            {
                "arm_group_label": "Arm 2: Lenalidomide + Dexamethasone + Elotuzumab", 
                "intervention_name": "Elotuzumab", 
                "intervention_type": "Biological", 
                "other_name": "BMS-901608"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Lenalidomide", 
                "Thalidomide", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 23, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Chrissy Raymundo, Site 7624", 
                    "phone": "415-221-4810"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Pacific Hematology Oncology Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Deneise Francis, Site 7613", 
                    "phone": "954-265-2796"
                }, 
                "facility": {
                    "address": {
                        "city": "Hollywood", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33021"
                    }, 
                    "name": "Memorial Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Thomas Sachdev, Site 7606", 
                    "phone": "309-243-3620"
                }, 
                "facility": {
                    "address": {
                        "city": "Peoria", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "61615"
                    }, 
                    "name": "Illinois Cancercare, Pc"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Steven Rubensetin, Site 7620", 
                    "phone": "317-859-5252"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46237"
                    }, 
                    "name": "Franciscan St. Francis Health"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nicole Guttierrez, Site 7614", 
                    "phone": "504-883-2968"
                }, 
                "facility": {
                    "address": {
                        "city": "Marrero", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70072"
                    }, 
                    "name": "Crescent City Research Consortium, LLC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michelle Messer, Site 1638", 
                    "phone": "614-366-4470"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Shanta Salzer, Site 7615", 
                    "phone": "843-792-1463"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University Of South Carolina Hollings Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sandra Dodd, Site 7628", 
                    "phone": "901-226-1473"
                }, 
                "facility": {
                    "address": {
                        "city": "Mephis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38120"
                    }, 
                    "name": "Baptist Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Susan Kinsella, Site 7623", 
                    "phone": "801-387-7166"
                }, 
                "facility": {
                    "address": {
                        "city": "Ogden", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84405"
                    }, 
                    "name": "Northern Utah Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 4651"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11528"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 5050"
                }, 
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "zip": "16132"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 5056"
                }, 
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy", 
                        "zip": "00161"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 5252"
                }, 
                "facility": {
                    "address": {
                        "city": "Chorzow", 
                        "country": "Poland", 
                        "zip": "41-500"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 5257"
                }, 
                "facility": {
                    "address": {
                        "city": "Lublin", 
                        "country": "Poland", 
                        "zip": "20-081"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Greece", 
                "Italy", 
                "Poland"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "For participation information at a USA site use a phone number below. For Site information outside USA please email"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time"
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Australia: National Health and Medical Research Council", 
                "Austria: Federal Office for Safety in Health Care", 
                "Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment", 
                "Canada: Health Canada", 
                "Czech Republic: State Institute for Drug Control", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Germany: Paul-Ehrlich-Institut", 
                "Germany: Federal Office for Radiation Protection", 
                "Germany: Ministry of Health", 
                "Greece: Ethics Committee", 
                "Greece: National Organization of Medicines", 
                "Hungary: National Institute of Pharmacy", 
                "Ireland: Irish Medicines Board", 
                "Israel: Israeli Health Ministry Pharmaceutical Administration", 
                "Italy: Ministry of Health", 
                "Italy: National Bioethics Committee", 
                "Italy: National Institute of Health", 
                "Italy: National Monitoring Centre for Clinical Trials - Ministry of Health", 
                "Italy: The Italian Medicines Agency", 
                "Poland: National Institute of Medicines", 
                "Poland: Ministry of Health", 
                "Poland: Ministry of Science and Higher Education", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Romania: National Medicines Agency", 
                "Russia: Ethics Committee", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Russia: FSI Scientific Center of Expertise of Medical Application", 
                "Spain: Spanish Agency of Medicines", 
                "Switzerland: Federal Office of Public Health", 
                "Switzerland: Swissmedic", 
                "Turkey: Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CS1=CD-2 subset 1\nMM=Multiple Myeloma", 
            "measure": "Change from baseline to progression of the cell surface expression of CS1 from bone marrow-derived MM cells in both treatment arms", 
            "safety_issue": "No", 
            "time_frame": "Screening (up to 30 days prior to first dose) and time of progression (33 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01891643"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Level of cell surface CS1 from bone marrow-derived MM cells in both treatment arms", 
                "safety_issue": "No", 
                "time_frame": "Time of progression (33 months)"
            }, 
            {
                "description": "sCS1=Soluble form of CS1", 
                "measure": "sCS1 levels in serum and to evaluate change from baseline and during therapy and at progression in both treatment arms", 
                "safety_issue": "No", 
                "time_frame": "Screening (up to 30 days prior to first dose), Cycle 3 Day 1 and time of progression (33 months)"
            }, 
            {
                "measure": "The presence, and the change from baseline, on therapy, and at progression, of circulating MM cell numbers and their CS1 cell surface expression in both treatment arms", 
                "safety_issue": "No", 
                "time_frame": "Screening (up to 30 days prior to first dose), Cycle 3 Day 1 and time of progression (33 months)"
            }, 
            {
                "measure": "The cell number and CS1 expression patterns between matched samples of bone marrow-derived MM cells and circulating MM cells at baseline and at progression in both treatment arms", 
                "safety_issue": "No", 
                "time_frame": "Screening (up to 30 days prior to first dose) and time of progression (33 months)"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "collaborator": {
                "agency": "Abbott", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}